Worldquant Millennium Advisors LLC Grows Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Worldquant Millennium Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX) by 1,165.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,365,441 shares of the medical equipment provider’s stock after purchasing an additional 1,257,550 shares during the quarter. Boston Scientific comprises approximately 0.8% of Worldquant Millennium Advisors LLC’s portfolio, making the stock its 21st largest holding. Worldquant Millennium Advisors LLC’s holdings in Boston Scientific were worth $121,961,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of BSX. Park Avenue Securities LLC increased its holdings in shares of Boston Scientific by 12.0% during the 4th quarter. Park Avenue Securities LLC now owns 12,869 shares of the medical equipment provider’s stock worth $1,149,000 after buying an additional 1,381 shares during the last quarter. Procyon Advisors LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $208,000. HB Wealth Management LLC increased its holdings in shares of Boston Scientific by 5.9% during the 4th quarter. HB Wealth Management LLC now owns 30,036 shares of the medical equipment provider’s stock worth $2,683,000 after buying an additional 1,676 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $658,000. Finally, Grove Bank & Trust increased its holdings in shares of Boston Scientific by 4.4% during the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider’s stock worth $261,000 after buying an additional 122 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,314 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the sale, the executive vice president now directly owns 22,235 shares of the company’s stock, valued at $2,269,304.10. The trade was a 43.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the completion of the sale, the chief executive officer now directly owns 1,535,706 shares of the company’s stock, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 263,163 shares of company stock valued at $27,129,540. Insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent analyst reports. Royal Bank of Canada raised their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an “outperform” rating in a report on Thursday, April 24th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, April 29th. Citigroup lifted their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Erste Group Bank upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, May 8th. Finally, UBS Group lifted their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Twenty-three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $114.74.

Boston Scientific Price Performance

Boston Scientific stock opened at $106.61 on Tuesday. The stock has a market cap of $157.72 billion, a P/E ratio of 85.29, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a fifty day simple moving average of $99.39 and a 200-day simple moving average of $96.90. Boston Scientific Co. has a 12-month low of $71.88 and a 12-month high of $107.36. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company’s revenue for the quarter was up 20.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.56 EPS. Equities analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.